ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / RNXT / earnings
OSTX (42) ZYBT (40) FBIO (39) MNOV (30) ⌘ Pro Terminal →

RenovoRx Inc. (RNXT) Next Earnings Date & Expected ±12.5% Move

$1.33 -10.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.30

RenovoRx Inc. (RNXT) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $67.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RNXT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RNXT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, RenovoRx Inc. (NASDAQ: RNXT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.33 (-10.74% 1D, market cap $67.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RNXT ranks #817 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RNXT compare to OSTX and ZYBT in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNXT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 70.9%, and ROIC of -35.0%. By comparison, OSTX (OS Therapies Incorporated) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $67.6M) and ZYBT (Zhengye Biotechnology Holding Limited (Class A)) posts a D- grade (40/100 RQD, P/E N/A, ROIC -22.3%, cap $67.8M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RNXT?
▼

Per RNXT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001574094), RenovoRx Inc. generated $1.1M in revenue (+2511.6% YoY), -$11.2M in net income, and -$11.0M in free cash flow against $8.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.30 (-2.12%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510031
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (3)Whales (11)SEC (8)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE RNXT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RNXT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY RNXT SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (35% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (26% of score)

Altman Z-Score 0.40 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
23
Grade E$1.28-10.9% Next Q
Q2 (-2Q)
26
Grade E$1.14+13.2% Next Q
Q3 (-1Q)
28
Grade E$1.29+3.1% Next Q
Current
31
Grade E$1.33-9.4% Hist 90D α
Trajectory: E (23) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RNXT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RNXT currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.56) and Max Pain ($1.40) forces dealer call-delta covering toward $2.72.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RNXT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RNXT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 31%NO 69%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$0.17 Expected Swing
$1.16 (-12.5%)Spot $1.33$1.50 (+12.5%)
MODEL EARNINGS SETUP GAUGE

RNXT Quantitative Pre-Earnings Setup: 31/100

Trailing EPS: $4.25 • YoY Revenue Growth: 180%

Model Bullish Setup (31/100)Model Risk Weight (69/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$1.1M-$11.2M-$11.0M70.9%
FY 20242024-12-31$43.0K-$8.8M-$9.1M98%
FY 20232023-12-31$0-$10.2M-$10.3M70.9%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RNXT)

  • ✓Walkthrough of RNXT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RNXT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +56.47%▲ ASCENDING TRIANGLE
2026-10-30O $1.49H $1.50L $1.30C $1.33VOL 376.4K
SUP: $1.14SMA50: $1.56SMA200: $1.10
$2.72$2.19$1.66$1.13$0.61SUP $1.14$1.332026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RNXT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RNXT Butterfly Map → + Track RNXT →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on RNXT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RNXT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RNXT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RNXT)

Health Care Rank #817 of 1016 ⚔️ OSTX vs RNXT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RNXT vs. OSTX, ZYBT, FBIO, MNOV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, RenovoRx Inc. (RNXT) ranks #817 by composite RQD confidence (31/100, grade E) and #713 by equity capitalization ($67.2M). Within this direct 5-issuer industry benchmark cohort, MNOV leads on earnings valuation at 5.7x trailing P/E, while ZYBT leads on capital efficiency and profitability with -22.3% ROIC and 20.5% gross margin. OSTX currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with RNXT at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RNXT ACTIVE
RenovoRx Inc.
E 31/100 — 70.9% -35.0% -10.74% $67.2M Benchmark Subject
OSTX
OS Therapies Incorporated
D- 42/100 — — -35.0% -4.61% $67.6M /ostx-vs-rnxt →
ZYBT
Zhengye Biotechnology Holding Limited (Class A)
D- 40/100 — 20.5% -22.3% -9.09% $67.8M /zybt-vs-rnxt →
FBIO
Fortress Biotech Inc.
D- 39/100 — 66.9% -35.0% -4.00% $66.7M /fbio-vs-rnxt →
MNOV
Medicinova Inc
E 30/100 5.7x — -35.0% 0.00% $68.9M /mnov-vs-rnxt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001574094

In its most recent audited fiscal period (FY2025, filed 2025-12-31), RenovoRx Inc. (RNXT) reported GAAP revenue of $1.1M (+2511.6% vs. FY2024 revenue of $43.0K ) , GAAP net income of -$11.2M, operating cash flow of -$11.0M, and free cash flow of -$11.0M (-20.1% YoY). On the balance sheet, RNXT closed FY2025 with $8.1M in total assets against $0 in total debt (Altman Z-Score: 0.40, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.1M -$11.2M -$11.0M -$11.0M $8.1M —
FY2024 (FY) 2024-12-31 $43.0K -$8.8M -$9.1M -$9.1M $8.1M —
FY2023 (FY) 2023-12-31 $0 -$10.2M -$10.3M -$10.3M — —

3. RNXT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RNXT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, RenovoRx Inc. (NASDAQ: RNXT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.33 (-10.74% 1D, market cap $67.2M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RNXT ranks #817 in composite RQD confidence.

How does RNXT compare to OSTX and ZYBT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNXT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 70.9%, and ROIC of -35.0%. By comparison, OSTX (OS Therapies Incorporated) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $67.6M) and ZYBT (Zhengye Biotechnology Holding Limited (Class A)) posts a D- grade (40/100 RQD, P/E N/A, ROIC -22.3%, cap $67.8M). Among the 5-stock peer group, MNOV leads on earnings multiple (5.7x) while ZYBT leads on capital efficiency (-22.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RNXT?

Per RNXT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001574094), RenovoRx Inc. generated $1.1M in revenue (+2511.6% YoY), -$11.2M in net income, and -$11.0M in free cash flow against $8.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RNXT trading relative to its 50-day, 200-day, and 52-week technical levels?

RNXT last traded at $1.33 (-10.74% on volume of 376,402 shares), positioning the stock -14.74% below its 50-day simple moving average ($1.56) and +20.91% above its 200-day simple moving average ($1.10). Across its 52-week range of $0.70 to $2.59, RNXT sits at the 33.3% percentile with a 14-day RSI of 47.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.16 to $1.50).

RNXT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is RNXT's next earnings date?

Based on SEC filing cadence, RenovoRx Inc. (RNXT)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is RNXT stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for RNXT, spanning a range between $1.16 and $1.5.

Direct Sub-Reports: RNXT RQD Cockpit RNXT 12M Forecast RNXT Earnings & Move RNXT Dividends & DRIP RNXT Insiders & 13F RNXT Whale Options RNXT Profit Sankey RNXT News & Why
ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

RNXT — RenovoRx Inc.: What the Facts Mean to a Prospective Investor

Engine: roarable-bundle-v1
As of: 2026-11-02T15:08:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD 5-pillar rating engine, RenovoRx Inc. (RNXT) carries a composite score of 31 / 100 (E — Roarable Strong Sell — Forensic Risk / Avoid).\n- Fundamental Cash Engine (3 / 20): Return on invested capital (ROIC) registers at -35.0% with a free cash flow yield of -16.32% and gross margin of 70.9%.\n- Institutional 13F Whale Flow (11 / 20): Tracks institutional accumulation and dark-pool/options positioning relative to the Biotechnology: Pharmaceutical Preparations cohort.\n- Insider & Congressional Conviction (3 / 20): Evaluates open-market Form 4 executive purchases and Congressional PTR disclosures.\n- Macro Regime Fit (6 / 20): Equity beta of 1.00 across the Health Care sector.\n- Forensic Balance-Sheet Shield (8 / 20): Altman Z-Score of 0.40, Piotroski F-Score of 4/9, and Debt-to-Equity of 0.50.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %\n------------------------------\n$1.33$67.2MN/AN/AN/AN/A0.00%1.00$0.70 - $2.59-35.0%

Business & Sector Positioning

RenovoRx Inc. (RNXT) is a NASDAQ-listed Health Care issuer operating in Biotechnology: Pharmaceutical Preparations with a market capitalization of $0.1B.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Operating within Biotechnology: Pharmaceutical Preparations (Health Care), RNXT exhibits an operating margin of -60.0% and net margin of -60.0%. Prospective investors should monitor 2nd-order capex cycles, input cost pass-through in gross margin (70.9%), and valuation discipline (current multiple) relative to free cash flow conversion.

Open Questions for Prospective Investors

  • How sustainable is RNXT's current operating margin (-60.0%) and ROIC (-35.0%) over the next four quarters?\n2. Does the current valuation multiple (current EV/EBITDA) adequately discount macro sensitivity (Beta 1.00) in Biotechnology: Pharmaceutical Preparations?\n3. Will upcoming quarterly cash flow conversion support continued balance-sheet strength (Altman Z 0.40)?

RNXT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for RenovoRx Inc. (RNXT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RNXT Debate Forum (3) ↓
🟡 MARKET WIRE Yahoo Finance • 69d ago
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

PK/PD Data is from a Sub-Study in the Phase III TIGeR-PaC Clinical Trial The Study Shows Approximately 51% Tumor-Site Drug Extraction, Decreased Systemic Exposure, and Significant Correlation Between Drug Metabolite Leve

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RNXT Bull vs. Bear Conversation Board — What's Your Call at $1.33?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RNXT 🐻 67% BEARISH CONVICTION
1. Pick Your Side on RNXT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.17 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is RNXT (E • RQD 31/100) a Buy at $1.33?

Welcome to the RNXT (RenovoRx Inc.) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.09 (-18.0%)
Spot @ $1.33

Pump the brakes on RNXT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on RNXT, but look at what you are paying: current EV/EBITDA multiples with 70.9% gross margins. Unless RenovoRx Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.54 (+15.8%)
Spot @ $1.33

RNXT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on RNXT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.33 (52-wk range $0.70 - $2.59), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%